This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruijne, N. Articles by Martin, D. Search for Related Content PubMed PubMed Citation Articles by Ruijne, N. Articles by Martin, D.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, July 2006, p. 797-801, Vol. 13, No. 7
1071-412X/06/$08.00+0     doi:10.1128/CVI.00038-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Understanding the Immune Responses to the Meningococcal Strain-Specific Vaccine MeNZB Measured in Studies of Infants

Institute of Environmental Science and Research (ESR), Porirua, New Zealand,¹ New Zealand Ministry of Health, Wellington, New Zealand,² Chiron Vaccines, Siena, Italy³

Received 29 January 2006/ Returned for modification 7 March 2006/ Accepted 4 May 2006

Vaccine trials with infants enrolled between 6 and 10 weeks of age (young infants) and 6 and 8 months of age (older infants) provided an opportunity to evaluate immunoglobulin G (IgG) isotype distribution and avidity maturation as indicators of antibody function and immunologic memory. Following vaccination with a strain-specific outer membrane vaccine, MeNZB, pre- and postvaccination sera were used to determine IgG isotype responses and avidity indices (AI) in subsets of vaccinated subjects. Measurements of IgG isotypes involved 100 infants from each trial. AI were measured in 50 infants from the young infant trial who received a fourth vaccine dose and in 40 older infants from whom serum was collected 7 months after the primary vaccination course. IgG1 and IgG3 dominated the responses to the vaccine. A modest linear correlation (P < 0.001) occurred between serum bactericidal antibody (SBAb) titers and the total IgG or the IgG1 antibody units in older infants. The young infants showed a modest linear correlation between SBAb and total IgG (P = 0.005) and a weak linear correlation between SBAb and IgG1 (P = 0.003). Increased avidity with age was demonstrated in both groups. The AI in the young infants increased from 51.5% (95% confidence interval [CI], 47.7 to 54.7) postvaccination to 68.7% (95% CI, 65.5 to 71.9%) following the fourth dose of vaccine (P < 0.001). The mean avidity of the older infants increased significantly (P = 0.00012) from 42.4% (95% CI, 39.1 to 45.3%) postvaccination to 50.4% (95% CI, 47.2 to 53.6%) 4 months later. A fourth dose of MeNZB is now being given to young infants at 10 months of age.

This article has been cited by other articles:

• Wedege, E., Bolstad, K., Aase, A., Herstad, T. K., McCallum, L., Rosenqvist, E., Oster, P., Martin, D. (2007). Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle Vaccines. CVI 14: 830-838 [Abstract] [Full Text]